Return to homepagePandemic Pact

University of Washington high risk outpatient trial

  • Funded by Gates Foundation, Wellcome Trust
  • Total publications:0 publications

Grant number: unknown

Grant search

Key facts

  • Disease

    COVID-19

  • Start & end year

    N/A

  • Funder

    Gates Foundation, Wellcome Trust

  • Principal Investigator

    Unspecified Unspecified Unspecified

  • Research Location

    United States of America

  • Lead Research Institution

    N/A

  • Research Priority Alignment

    N/A

  • Research Category

    Therapeutics research, development and implementation

  • Research Subcategory

    Clinical trial (unspecified trial phase)

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Unspecified

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

Targets high-risk patients in the outpatient setting initially using hydroxychloroquine (HCQ), HCQ + azithromycin (AZ), and Kaletra to treat mild COVID-19. HCQ and HCQ+AZ arms were discontinued in late July and the study is moving forward with Kaletra.